Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 10NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell, Marginal Zone 3Waldenstrom Macroglobulinemia 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, AIDS-Related 1Leukemia, Hairy Cell 1HIV Infections 1Classic Follicular Lymphoma 1Burkitt Lymphoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1Anemia 1

Interventions

Cyclophosphamide 31Rituximab 22Vincristine 19Doxorubicin 17Filgrastim 15Prednisone 14Peripheral Blood Stem Cell Transplantation 14Etoposide 13Cytarabine 12Magnetic Resonance Spectroscopy 10fludarabine phosphate 9Radiotherapy 9Bortezomib 9Biopsy 9Cyclosporine 8Specimen Handling 7Methotrexate 7Dexamethasone 7X-Rays 6Vorinostat 6Phantoms, Imaging 6Leucovorin 6Lenalidomide 6tanespimycin 5sargramostim 5fludarabine 5bryostatin 1 5aldesleukin 5Nuclear Medicine Department, Hospital 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Non-Hodgkin × CT-P10 × Clear all
NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
9 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡